Table 2 Effect of protease-activated kringles 1–5 administration on joint destruction
Normal | Mild | Moderate | Severe | |
|---|---|---|---|---|
Distal phalanx joints | ||||
Untreated* | 0 (0%) | 3 (60%) | 2 (40%) | 0 (0%) |
Vehicle | 3 (37%) | 0 (0%) | 4 (50%) | 1 (13%) |
K1–5 0.2 mg/kg ** | 0 (0%) | 2 (33%) | 1 (17%) | 3 (50%) |
K1–5 2 mg/kg | 6 (86%) | 0 (0%) | 1 (14%) | 0 (0%) |
Proximal phalanx joints | ||||
Untreated | 4 (25%) | 2 (12%) | 2 (12%) | 8 (50%) |
Vehicle* | 1 (6%) | 4 (27%) | 0 (0%) | 10 (67%) |
K1–5 0.2 mg/kg** | 1 (8%) | 1 (8%) | 0 (0%) | 10 (83%) |
K1–5 2 mg/kg | 7 (54%) | 2 (15%) | 1 (8%) | 3 (23%) |
First metatarsal joints | ||||
Untreated | 4 (25%) | 1 (6%) | 1 (6%) | 10 (63%) |
Vehicle | 1 (5%) | 5 (28%) | 3 (17%) | 9 (50%) |
K1–5 0.2 mg/kg | 1 (7%) | 3 (20%) | 2 (13%) | 9 (60%) |
K1–5 2 mg/kg | 3 (20%) | 1 (7%) | 3 (20%) | 8 (53%) |
Tarsal joints | ||||
Untreated | 2 (15%) | 1 (7%) | 2 (15%) | 8 (62%) |
Vehicle | 2 (14%) | 3 (21%) | 3 (21%) | 6 (43%) |
K1–5 0.2 mg/kg | 1 (8%) | 0 (0%) | 5 (42%) | 6 (50%) |
K1–5 2 mg/kg | 2 (17%) | 1 (8%) | 4 (33%) | 5 (42%) |